The store will not work correctly when cookies are disabled.
N-(6-Fluorobenzothiazol-2-yl)-4-chlorobenzamide
ID: ALA4553487
Cas Number: 392289-83-7
PubChem CID: 953540
Max Phase: Preclinical
Molecular Formula: C14H8ClFN2OS
Molecular Weight: 306.75
Molecule Type: Unknown
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(Nc1nc2ccc(F)cc2s1)c1ccc(Cl)cc1
Standard InChI: InChI=1S/C14H8ClFN2OS/c15-9-3-1-8(2-4-9)13(19)18-14-17-11-6-5-10(16)7-12(11)20-14/h1-7H,(H,17,18,19)
Standard InChI Key: OUYQJFKJIPSUCO-UHFFFAOYSA-N
Molfile:
RDKit 2D
20 22 0 0 0 0 0 0 0 0999 V2000
2.9372 -1.6756 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9360 -2.4952 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6441 -2.9041 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6423 -1.2668 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3509 -1.6720 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.3557 -2.4906 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1357 -2.7391 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
5.6131 -2.0740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1280 -1.4146 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.4303 -2.0691 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
6.8430 -2.7744 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.6602 -2.7696 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.4386 -3.4845 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
8.0709 -3.4770 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.8874 -3.4726 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.2926 -2.7619 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.8754 -2.0543 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.0604 -2.0623 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.2280 -2.9032 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
10.1098 -2.7560 0.0000 Cl 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0
2 3 1 0
3 6 2 0
5 4 2 0
4 1 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 2 0
9 5 1 0
8 10 1 0
10 11 1 0
11 12 1 0
11 13 2 0
12 14 2 0
14 15 1 0
15 16 2 0
16 17 1 0
17 18 2 0
18 12 1 0
2 19 1 0
16 20 1 0
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 306.75 | Molecular Weight (Monoisotopic): 306.0030 | AlogP: 4.34 | #Rotatable Bonds: 2 |
Polar Surface Area: 41.99 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: ┄ | HBA (Lipinski): 3 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 11.24 | CX Basic pKa: ┄ | CX LogP: 4.64 | CX LogD: 4.64 |
Aromatic Rings: 3 | Heavy Atoms: 20 | QED Weighted: 0.76 | Np Likeness Score: -2.79 |
References
1. Zaldivar-Diez J, Li L, Garcia AM, Zhao WN, Medina-Menendez C, Haggarty SJ, Gil C, Morales AV, Martinez A.. (2020) Benzothiazole-Based LRRK2 Inhibitors as Wnt Enhancers and Promoters of Oligodendrocytic Fate., 63 (5): [PMID:31825616] [10.1021/acs.jmedchem.9b01752] |